Hoogerbrugge

Peter Hoogerbrugge is a pediatric oncologist with special interest in the biology of childhood acute lymphoblastic leukemia (ALL), both from the clinical perspective and from the 'bench-perspective'. Current projects of the lab, headed by Dr Frank van Leeuwen, in close collaboration with the lab of the department of genetics (Dr Kuiper and Prof GeurtsvanKessel), aim at identifying novel genetic defects leading to therapy resistance and relapses in childhood ALL. Recently, the group identified Ikaros-deletions as a poor prognostic factor in ALL, based on which treatment will be adjusted in he near future. The studies include fresh leukemic samples in collaboration with the Dutch Childhood Oncology Grouop (DCOG), cell-lines and murine models. Peter Hoogerbrugge chairs the DCOG-relapsed-ALL study committee and is co-investigator in EG-funded studies on relapsed ALL in children (IntreALL). In collaboration with Prof. Adema, research on the role of immunotherapy in high-risk neuroblastoma is performed in murine models of neuroblastoma.

• Jongmans MC, van der Burgt I, Hoogerbrugge PM, Noordam K, Yntema HG, Nillesen WM, Kuiper RP, Ligtenberg MJ, van Kessel AG, van Krieken JH, Kiemeney LA, Hoogerbrugge N. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet. 19:870-4, 2011.

• Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V, Veerman AJ, van Kessel AG, Hoogerbrugge PM, Kuiper RP, van Dongen JJ. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia. 25:254-8, 2010. 

• Langemeijer SM, Jansen JH, Hooijer J, van Hoogen P, Stevens-Linders E, Massop M, Waanders E, van Reijmersdal SV, Stevens-Kroef MJ, Zwaan CM, van den Heuvel-Eibrink MM, Sonneveld E, Hoogerbrugge PM, van Kessel AG, Kuiper RP. TET2 mutations in childhood leukemia. Leukemia. 25:189-92, 2011.

• Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van Dongen JJ, Veerman AJ, van Leeuwen FN, van Kessel AG, Hoogerbrugge PM. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 24:1258-64, 2010.

• van Galen JC, Kuiper RP, van Emst L, Levers M, Tijchon E, Scheijen B, Waanders E, van Reijmersdal SV, Gilissen C, van Kessel AG, Hoogerbrugge PM, van Leeuwen FN. BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood. 115:4810-9, 2010.